Educational Intervention Aids Problematic Hypoglycemia

Share this content:
Educational Intervention Aids Problematic Hypoglycemia
Educational Intervention Aids Problematic Hypoglycemia

TUESDAY, Nov. 1, 2016 (HealthDay News) -- A brief, partly web-based educational intervention, HypoAware, is beneficial for reducing severe hypoglycemic episodes and improving hypoglycemia awareness compared with usual care, according to a study published online Oct. 20 in Diabetes Care.

Stefanie M.P.A. Rondags, from the VU University Medical Center in Amsterdam, and colleagues enrolled 137 insulin-treated patients with problematic hypoglycemia in eight Dutch clinics to compare HypoAware care with usual care. The authors assessed self-reported severe hypoglycemia, impaired hypoglycemia awareness, and worries and distress about hypoglycemia at baseline and at two, four, and six months of follow-up.

The researchers found that, compared with the control group, the HypoAware group had 33 percent fewer episodes of severe hypoglycemia (relative risk [RR], 0.67; 95 percent confidence interval [CI], 0.39 to 1.16). They also had significantly reduced odds of impaired awareness (odds ratio, 0.38; 95 percent CI, 0.15 to 0.95), a trend toward fewer worries about hypoglycemia (RR, 0.80; 95 percent CI, 0.64 to 1.01), and a significant reduction in hypo-distress (RR, 0.70; 95 percent CI, 0.56 to 0.88). Participants experienced a median of 2.5 events of severe hypoglycemia in the control condition versus one event in the HypoAware event over the six-month study duration (P = 0.030).

"HypoAware resulted in fewer severe hypoglycemic episodes, significantly improved hypoglycemia awareness, and less hypo-distress in comparison with usual care, and deserves further dissemination," the authors write.

The study was partially funded by Novo Nordisk and Agis Achmea, a Dutch health care insurer.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »